Amalgamated Bank purchased a new position in PRA Health Sciences, Inc. (NASDAQ:PRAH) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 4,930 shares of the medical research company’s stock, valued at approximately $370,000.

Several other institutional investors have also made changes to their positions in the business. First Bank & Trust increased its holdings in shares of PRA Health Sciences by 1.6% in the second quarter. First Bank & Trust now owns 3,211 shares of the medical research company’s stock worth $241,000 after acquiring an additional 52 shares in the last quarter. Renaissance Group LLC increased its holdings in shares of PRA Health Sciences by 2.5% in the second quarter. Renaissance Group LLC now owns 5,239 shares of the medical research company’s stock worth $393,000 after acquiring an additional 126 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of PRA Health Sciences by 12.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock worth $112,000 after acquiring an additional 160 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. increased its holdings in shares of PRA Health Sciences by 1.9% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 8,505 shares of the medical research company’s stock worth $638,000 after acquiring an additional 160 shares in the last quarter. Finally, Eqis Capital Management Inc. increased its holdings in shares of PRA Health Sciences by 6.5% in the second quarter. Eqis Capital Management Inc. now owns 4,217 shares of the medical research company’s stock worth $316,000 after acquiring an additional 259 shares in the last quarter. Institutional investors own 98.37% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Amalgamated Bank Takes $370,000 Position in PRA Health Sciences, Inc. (PRAH)” was published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/10/08/amalgamated-bank-takes-370000-position-in-pra-health-sciences-inc-prah.html.

In other PRA Health Sciences news, CEO Colin Shannon sold 400,000 shares of PRA Health Sciences stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $74.85, for a total transaction of $29,940,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Pra Investors L.P. Kkr sold 9,500,000 shares of PRA Health Sciences stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $74.85, for a total value of $711,075,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 10,000,000 shares of company stock valued at $748,500,000 in the last quarter. Company insiders own 2.10% of the company’s stock.

PRAH has been the subject of several recent analyst reports. BidaskClub downgraded PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Citigroup Inc. restated a “buy” rating and issued a $90.00 price target (up from $73.00) on shares of PRA Health Sciences in a report on Wednesday, June 28th. Bank of America Corporation initiated coverage on PRA Health Sciences in a report on Monday, June 26th. They issued a “buy” rating and a $89.00 price target for the company. Zacks Investment Research upgraded PRA Health Sciences from a “hold” rating to a “buy” rating and set a $83.00 price target for the company in a report on Tuesday, August 15th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $92.00 price objective (up from $88.00) on shares of PRA Health Sciences in a research report on Thursday, August 10th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. PRA Health Sciences currently has a consensus rating of “Buy” and an average price target of $84.22.

PRA Health Sciences, Inc. (NASDAQ:PRAH) opened at 79.81 on Friday. The stock’s 50 day moving average price is $76.29 and its 200 day moving average price is $72.03. PRA Health Sciences, Inc. has a 52-week low of $50.87 and a 52-week high of $80.99. The firm has a market capitalization of $5.00 billion, a PE ratio of 51.52 and a beta of 0.42.

PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Monday, August 7th. The medical research company reported $0.62 EPS for the quarter, missing analysts’ consensus estimates of $0.72 by ($0.10). The firm had revenue of $457.90 million during the quarter, compared to the consensus estimate of $447.79 million. PRA Health Sciences had a net margin of 5.15% and a return on equity of 21.17%. The business’s quarterly revenue was up .5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.63 earnings per share. On average, analysts predict that PRA Health Sciences, Inc. will post $3.18 EPS for the current fiscal year.

PRA Health Sciences Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences, Inc. (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.